This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Pompen M, Novak A, Postmus P, Gok M, Gyldmark M.Pharmacoeconomic analysis of the treatment of non-small cell lung cancer in the Netherlands demonstrates that erlotinib dominates docetaxel and is cost-effective over best supportive care without need for patient stratification. Value in Health 9: A203 (plus oral presentation) abstr. CN3, No. 6, Nov-Dec 2006
Lewis G, Morlotti L, Creeden J, Gyldmark M, Peake MD.Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non-small cell lung cancer in the UK. Value in Health 9: A203-A204 (plus oral presentation) abstr. CN4, No. 6, Nov-Dec 2006
Côté I, Leighl NB, Gyldmark M, Maturi B.Pharmacoeconomic analyses of erlotinib compared with best supportive care for the treatment of relapsed non-small cell lung cancer from the Canadian public health care perspective. Value in Health 9: A279 (plus poster) abstr. PCN11, No. 6, Nov-Dec 2006
Orlewska E, Szczesna A, Gyldmark M, Szkultecka-debek M.Cost effectiveness of erlotinib in the treatment of advanced non small cell lung cancer in Poland. Value in Health 9: A279 (plus poster) abstr. PCN12, No. 6, Nov-Dec 2006
Rubio Terres C, Alvarez Sanz C, Marlene Gylmark GM.Pharmacoeconomic analysis in Spain of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced non-small cell lung cancer who have failed previous chemotherapy regimens. Value in Health 9: A283-A284 (plus poster) abstr. PCN26, No. 6, Nov-Dec 2006
Rights and permissions
About this article
Cite this article
Erlotinib breathes new life into NSCLC treatments. Pharmacoecon. Outcomes News 516, 3–4 (2006). https://doi.org/10.2165/00151234-200605160-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605160-00005